Skip to Content
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site
Last Updated: 10/02/22

Publications

Title Year of Publication
NCI Workshop on ctDNA in Cancer Treatment and Clinical Care Brian S Sorg, Jung S Byun, V Anne Westbrook, James V Tricoli, James H Doroshow, Lyndsay N Harris. J Natl Cancer Inst (2024) 2024
Upregulation of TET2 and Resistance to DNA Methyltransferase (DNMT) Inhibitors in DNMT1-Deleted Cancer Cells Angelo B A Laranjeira, Dat Nguyen, Lorraine C Pelosof, James H Doroshow, Sherry X Yang. Diseases (2024) 2024
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial Sherry X Yang, John Yu, Molin Wang. J Natl Cancer Inst (2024) 2024
Resource requirements to accelerate clinical applications of next generation sequencing and radiomics: Workshop commentary and review Lyndsay Harris, Lalitha K Shankar, Claire Hildebrandt, Wendy S Rubinstein, Kristofor Langlais, Henry Rodriguez, Adam Berger, John Freymann, Erich P Huang, P Mickey Williams, Jean Claude Zenklusen, Robert Ochs, Zivana Tezak, Berkman Sahiner. J Natl Compr Canc Netw (2024) 2024
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B Philippe L Bedard, Shuli Li, Kari B Wisinski, Eddy S Yang, Sewanti A Limaye, Edith P Mitchell, James A Zwiebel, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty. JCO Precision Oncology (2022) 2022
Organocatalyst treatment improves variant calling and mutant detection in archival clinical samples Leah C Wehmas, Charles E Wood, Ping Guan, Mark Gosink, Susan D Hester. Scientific Reports (2022) 2022
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922) Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, Kari L Kendra, George Ansstas, Gino K In, Peng Wang, Glenn Liu, Frances A Collichio, Paul B Googe, Craig C Carson, Karen McKinnon, Hsing-Hui Wang, Nana Nikolaishvilli-Feinberg, Anastasia Ivanova, Christy C Arrowood, Nancy Garrett-Mead, Kathleen C Conway, Sharon N Edmiston, David W Ollila, Jonathan S Serody, Nancy E Thomas, S Percy Ivy, Lokesh Agrawal, Elizabeth C Dees, James L Abbruzzese. Melanoma Research (2022) 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial Olive S Eckstein, Carl E Allen, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M Reid, Jin Piao, Lauren Saguilig, Todd A Alonzo, Stacey L Berg, Nilsa C Ramirez, Alok Jaju, Joyce Mhlanga, Elizabeth Fox, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, James V Tricoli, Katherine A Janeway, Nita L Seibel, D Williams Parsons. Journal of Clinical Oncology (2022) 2022
Locoregional tumor burden and risk of mortality in metastatic breast cancer Sherry X Yang, Stephen M Hewitt, John Yu. NPJ Precision Oncology (2022) 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial D Williams Parsons, Katherine A Janeway, David R Patton, Cynthia L Winter, Brent Coffey, P Mickey Williams, Sinchita Roy-Chowdhuri, Gregory J Tsongalis, Mark Routbort, Nilsa C Ramirez, Lauren Saguilig, Jin Piao, Todd A Alonzo, Stacey L Berg, Elizabeth Fox, Douglas S Hawkins, Jeffrey S Abrams, Margaret Mooney, Naoko Takebe, James V Tricoli, Nita L Seibel, NCI-COG Pediatric MATCH Team. Journal of Clinical Oncology (2022) 2022
Evaluation of Tumor Development Using Hemoglobin Saturation Profile on Rodent Dorsal Window Chamber Miguel R Ossandon, Brian S Sorg, Dhananjay S Phatak, Konstantinos Kalpakis. Methods in Molecular Biology (2022) 2022
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components Geraldine O'Sullivan Coyne, Chris Karlovich, Deborah Wilsker, Andrea Regier Voth, Ralph E Parchment, Alice P Chen, James H Doroshow. OncoTargets and Therapy (2022) 2022
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, Josh D Lauring, Edith P Mitchell, James A Zwiebel, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinstein, David Patton, P Mickey Williams, Stanley R Hamilton, Scott A Kono, James M Ford, Agustin A Garcia, Xingwei D Sui, Robert D Siegel, Brian M Slomovitz, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty. JCO Precision Oncology (2022). 2022
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. Senthil Damodaran, Fengmin Zhao, Dustin A Deming, Edith P Mitchell, John J Wright, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, Jennifer M Suga, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty. Journal of Clinical Oncology (2022). 2022
GA4GH: International policies and standards for data sharing across genomic research and healthcare Exit Disclaimer Heidi L. Rehm, Angela J.H. Page, Lindsay Smith, Esmeralda Casas-Silva, et al. Cell Genomics (2021) 2021
TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models. Exit Disclaimer Sherry X. Yang, Melinda Hollingshead, Larry Rubinstein, Dat Nguyen, Angelo B. A. Larenjeira, Robert J. Kinders, Michael Difilippantonio, James H. Doroshow. Journal of Hematology & Oncology (2021) 2021
Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry. Aditi Bagchi, Zachary Madaj, Kelly B Engel, Ping Guan, Daniel C Rohrer, Dana R Valley, Emily Wolfrum, Kristin Feenstra, Nancy Roche, Galen Hostetter, Helen M Moore, Scott D Jewell. Journal of Histochemistry & Cytochemistry (2021) 2021
The GTEx Consortium atlas of genetic regulatory effects across human tissues. GTEx Consortium. Science. (2020) 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) Keith T Flaherty, Robert J Gray, Alice P Chen, Shuli Li, Lisa M McShane, David Patton, Stanley R Hamilton, P Mickey Williams, A John Iafrate, Jeffrey Sklar, Edith P Mitchell, Lyndsay N Harris, Naoko Takebe, David J Sims, Brent Coffey, Tony Fu, Mark Routbort, James A Zwiebel, Larry V Rubinstein, Richard F Little, Carlos L Arteaga, Robert Comis, Jeffrey S Abrams, Peter J O'Dwyer, Barbara A Conley, NCI-MATCH team Journal of Clinical Oncology (2020) 2020
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working Group  Exit Disclaimer James H Godsey, Angela Silvestro, J Carl Barrett, Kelli Bramlett, Darya Chudova, Ina Deras, Jennifer Dickey, James Hicks, Donald J Johann, Rebecca Leary, Jerry S H Lee, Joe McMullen, Lisa McShane, Katherine Nakamura, Aaron O Richardson, Matthew Ryder, John Simmons, Kelli Tanzella, Laura Yee, Lauren C Leiman. Clinical Chemistry (2020) 2020
Harmonizing cell-free DNA Collection and Processing Practices through Evidence-based Guidance. Sarah R Greytak, Kelly B Engel, Sonya Parpart-Li, Muhammed Murtaza, Abel J Bronkhorst, Mark D Pertile, Helen M Moore. Clinical Cancer Research (2020). 2020
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Orit Rozenblatt-Rosen, Aviv Regev, Philipp Oberdoerffer, Tal Nawy, Anna Hupalowska, Jennifer E. Rood, Orr Ashenberg, Ethan Cerami, Robert J. Coffey, Emek Demir, Li Ding, Edward D. Esplin, James M. Ford, Jeremy Goecks, Sharmistha Ghosh, Joe W. Gray, Justin Guinney, Sean E. Hanlon, Shannon K. Hughes, E. Shelley Hwang, Christine A. Iacobuzio-Donahue, Judit Jané-Valbuena, Bruce E. Johnson, Ken S. Lau, Tracy Lively, Sarah A. Mazzilli, Dana Pe’er, Sandro Santagata, Alex K. Shalek, Denis Schapiro, Michael P. Snyder, Peter K. Sorger, Avrum E. Spira, Sudhir Srivastava, Kai Tan, Robert B. West, Elizabeth H. Williams, and the Human Tumor Atlas Network. Cell (2020). 2020
Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials Exit Disclaimer Hala Makhlouf, MD, PhD, Mark A Watson, MD, PhD, Heather A Lankes, PhD, MPH, Carol Weil, JD, Maura Dickler, MD, Michael Birrer, MD, PhD, Christopher Moskaluk, MD, PhD, Nilsa C Ramirez, MD, Nader Okby, MD, Edgar Alonsozana, MD, Mark Barnes, JD, LLM, Edward B Goldman, JD, Rebecca Enos, ADN, MPH, Irina Lubensky, MD. American Journal of Clinical Pathology (2019) 2019
Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials. Yee LM1, McShane LM, Freidlin B, Mooney MM, Korn EL. The Cancer Journal (2019) 2019
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology Exit Disclaimer   Roberto Salgado, David B. Solit, David L.Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, Paul N Span et al. European Journal of Cancer Exit Disclaimer   (2019) 2019
Deleterious effects of formalin-fixation and delays to fixation on RNA and miRNA-Seq profiles Exit Disclaimer   Wendell Jones, Sarah Greytak, Hana Odeh, Ping Guan, Jason Powers, Jasmin Bavarva & Helen M. Moore. Scientific Reports  (2019) 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, et al. JAMA Oncology (2019) 2019
Critical Financial Challenges for Biobanking: Report of a National Cancer Institute Study Abhi Rao, Jim Vaught, Bill Tulskie, Dorie Olson, Hana Odeh, Jeffrey McLean, Helen M Moore. Biopreservation and biobanking. (2019) 2019
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. Sauberbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. JNCI: Journal of the National Cancer Institute. (2018) 2018
Circulating Tumor DNA Assays in Clinical Cancer Research Exit Disclaimer   Miguel Ossandon et al. JNCI: Journal of the National Cancer Institute. (2018) 2018
A mutational comparison of adult and adolescent and young adult (AYA) colon cancer. JV Tricoli et al. Cancer. (2018). 2018
Development of a consensus approach for return of pathology incidental findings in the Genotype-Tissue Expression (GTEx) project. Lockhart et al. Journal of Medical Ethics. (2018) 2018
Biomarkers in early-phase trials: fundamental issuesExit Disclaimer   Laura M Yee et al. Future Science. (2018) 2018
Broad Consent for Research on Biospecimens: The Views of Actual Donors at Four U.S. Medical Centers. Exit Disclaimer   Warner TD, Weil CJ, Andry C, Degenholtz HB, Parker L, Carithers LJ, Feige M, Wendler D, Pentz RD. J Empir Res Hum Res Ethics. 2018 Jan 1:1556264617751204. doi: 10.1177/1556264617751204. [Epub ahead of print] PMID: 29390947 2018
Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Exit Disclaimer   L Agrawal et al. Seminars in Cancer Biol. (2017). 2017
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference. VN Giri et al. J Clin Oncol. (2017). 2017
Evaluation of a Methodology for Automated Cell Counting for Streak Mode Imaging Flow Cytometry. Exit Disclaimer   M Ossandon et al. Journal of Analytical & Bioanalytical Techniques. (2017). 2017
A Non-Gas-Based Cryotherapy System for the Treatment of Cervical Intraepithelial Neoplasia: A Mixed-Methods Approach for Initial Development and Testing. M Cremer et al. Glob Health Sci Pract. (2017) 2017
Non-alcoholic Steatofibrosis Independently Predicts Mortality in Non-alcoholic Fatty Liver Disease. Exit Disclaimer   Z Younoszai et al. Hepatology Communications. (2017). 2017
Characterization of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. CF Spraggs et al. Pharmacogenomics J. (2017). 2017
Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial (NCI-MATCH, EAY131). Exit Disclaimer   Lih C-J, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. J. Mol. Diagn. (2017) 19:313-327. 2017
Development and validation of a Luminex assay for detection of a predictive biomarker for ROSTVAC-VF therapy. Lucas JL, Tacheny EA, Ferris A, Galusha M, Srivastava AK, Ganguly A, Williams PM, Sachs MC, Thurin M, Tricoli JV, Ricker W, Gildersleeve JC. PLoS One. (August 2017) 2(8):e0182739. PMID: 28771597 2017
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Exit Disclaimer   Khoury JD, Wang W-L, Prieto VG, Medeiros LJ, Kalhor N, Hameed M, Broaddus R, Hamilton SR. Clin. Cancer Res. (August 2017) DOI: 10.1158/1078-0432.CCR-17-1597 2017
Immunotherapy biomarkers 2016: overcoming the barriers. Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH. J Immunother Cancer. 2(March 2017) 5(1):29. doi: 10.1186/s40425-017-0225-6. 2017
Nanotechnology Platforms and Physiological Challenges for Cancer Therapeutics. Kim, KY. Nanomedicine's Most Cited - Volume 1: Nanomedicine in Cancer, pp. 1-15, Balogh, Lajos P. (ed.). Singapore: Pan Stanford Publishing Pte. Ltd., 2017. ISBN: 9789814745802 [invited book chapter] 2017
Clinical Utility of Epstein-Barr Virus DNA Testing in the Management of Nasopharyngeal Carcinoma Patients. Kim KY, Le QT, Yom SS, Ng RHW, Chan KCA, Bratman SV, Welch JJ, Divi RL, Petryshyn RA, Conley BA. International Journal of Radiation Oncology Biology Physics (August 2017) 98(5):996-1001. 2017
A computational streak mode cytometry biosensor for rare cell analysis. M Ossandon et al. Analyst. (2017). 2017
Streak Imaging Flow Cytometer for Rare Cell Analysis. J Balsam et al. Methods Mol Biol. (2017) 2017
The Role of Affordable, Point-of-Care Technologies for Cancer Care in Low- and Middle-Income Countries: A Review & Commentary. Exit Disclaimer   K Haney et al. IEEE Transl Engineering in Health and Med. (2017). 2017
India-U.S. Dialogue on Traditional Medicine — Towards Collaborative Research and Generation of an Evidence Base. Exit Disclaimer   JD White et al. J Global Oncology. (2017). 2017
Predictive Markers and Driver Genes from Treatment Trials: Potential Utility for Early Diagnosis. Exit Disclaimer   BS Sorg et al. Biomarkers in Cancer Screening and Early Detection. Srivastava S., editor. Wiley-Blackwell (2017) Chapter 19, p. 231-245. 2017
Biliary Adenofibroma of Liver: Morphology, Tumor Genetics, and Outcomes in 6 Cases. T Arnason et al. Am J Surg Pathol. (2017). 2017
Decoding NADPH oxidase 4 expression in human tumors. JL Meitzler et al. Redox Biol. (2017). 2017
The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes. MT Knobf et al. Heart Lung. 2017 2017
The Biology of AYA Cancers. Exit Disclaimer   JV Tricoli. Cancer in Adolescents and Young Adults. Second edition, Bleyer R, Barr R, Ries L, Whelan J, Ferrari A (eds.), Springer-Verlag (2017). 2017
Pediatric oncology enters the era of precision medicine. SL Seibel et al. Current Problems in Cancer. (2017). 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Exit Disclaimer   A Sonnenblick et al. J. Clin. Oncol. (2017). 2017
The Challenge for Development of Valuable Immunooncology Biomarkers. JM Mehnert et al. Clin Cancer Res. (2017). 2017
Steps forward for cancer precision medicine. R Salgado et al. Nat Rev Drug Discov. (2017). 2017
Societal challenges of precision medicine: Bringing order to chaos. R Salgado et al. Eur J Cancer. (2017). 2017
Decoding NADPH oxidase 4 expression in human tumors. Exit Disclaimer   Metzler JL, Maklouf HR, Antony S, Wu Y, Butcher D, Jiang G, Juhasz A, Lu J, Dahan I, Jansun-Dürr P, Pircher H, Shah AM, Roy K, Doroshow JH. Redox Biology 13, pp 182-195 (October 2017). doi: 10.1016/j.redox.2017.05.016 2017
NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1α and p27Kip1 expression in malignant melanoma and other human tumors. Exit Disclaimer   Antony S, Jiang G, We Y, Meitzler J, Makhlouf HR, Haines DC, Butcher D, Hoon SD, Ji J, Zhang Y, Juhasz A, Lu J, Liu H, Dahan I, Konate M, Roy KK, Doroshow JH. Molecular Carcinogenesis (August 2017) doi: 10.1002/mc.22708 2017
Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Exit Disclaimer   The Cancer Genome Atlas Research Network. Cell 169, pp. 1327-1341 (June 2017) doi: 10.1016/j.cell.2017.05.046 2017
Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. Kim KY, Le Q-T, Yom SS, Ng RHW, Chan KCA, Bratman SV, Welch JJ, Divi RL, Petryshyn RA, Conley BA. JNCI J Natl Cancer Inst (2017) 109(4): djx007.10.1016/j.ijrobp.2017.03.018. 2017